Weight loss gummies claim to burn fat, suppress hunger, and boost your metabolism to help with weight loss, but these ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global phase 3 trial in patients with acquired hypothalamic ...

"Our global trial of setmelanotide in patients with acquired hypothalamic obesity - which is on track for topline data readout in the second quarter of 2025 - is being conducted in North America, ...

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) has reacquired the rights to its obesity treatment Imcivree (setmelanotide) in China, Hong Kong and Macau, after terminating a 2021 licensing agreement ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a $3.4 billion biopharmaceutical company specializing in rare neuroendocrine diseases, has reclaimed the rights to its obesity drug, IMCIVREE® ...